Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cerilliant
US Army
US Department of Justice
Citi
Queensland Health
Chinese Patent Office
McKesson
Harvard Business School
Chubb

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206321

« Back to Dashboard
NDA 206321 describes SAXENDA, which is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from one supplier. There are fifteen patents protecting this drug. Additional details are available on the SAXENDA profile page.

The generic ingredient in SAXENDA is liraglutide recombinant. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the liraglutide recombinant profile page.

Summary for NDA: 206321

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:15
Formulation / Manufacturing:see details

Pharmacology for NDA: 206321

Suppliers and Packaging for NDA: 206321

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS 206321 NDA Novo Nordisk 0169-2800 0169-2800-15 5 SYRINGE, PLASTIC in 1 CARTON (0169-2800-15) > 3 mL in 1 SYRINGE, PLASTIC
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS 206321 NDA Novo Nordisk 0169-2800 0169-2800-90 1 SYRINGE, PLASTIC in 1 CARTON (0169-2800-90) > 3 mL in 1 SYRINGE, PLASTIC

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength18MG/3ML (6MG/ML)
Approval Date:Dec 23, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 25, 2017
Regulatory Exclusivity Use:NEW PRODUCT
Patent:► SubscribePatent Expiration:Aug 22, 2022Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
Patent:► SubscribePatent Expiration:Aug 22, 2017Product Flag?YSubstance Flag?YDelist Request?
Patented Use:METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY

Expired Orange Book Patents for NDA: 206321

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014► Subscribe► Subscribe
Novo Nordisk Inc
SAXENDA
liraglutide recombinant
SOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
AstraZeneca
UBS
Teva
Moodys
Accenture
Argus Health
Queensland Health
Cipla
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot